Your session is about to expire
← Back to Search
ARROW Trial Summary
This trial is testing a new drug, pralsetinib, to see if it is safe and effective in treating medullary thyroid cancer, RET-altered non-small cell lung cancer, and other RET-altered solid tumors.
- Papillary Thyroid Cancer
- Lung Disease
- Head and Neck Cancers
- Germ Cell Tumors
- Intestinal Tumors
- Non-Small Cell Lung Cancer
- Lung Cancer
- Intestinal Diseases
- Endocrine Disorders
- Medullary Thyroid Cancer
- Colorectal Cancer
- Solid Tumors
- Endocrine Tumors
- Bronchial Tumors
- Neuroendocrine Tumors
- Digestive System Tumors
- Gastrointestinal Disorders
- Colonic Diseases
- Gastrointestinal Tumors
- Neuroendocrine Carcinoma
- Gastrointestinal Disease
- Papillary Adenocarcinoma
- Respiratory Diseases
- Thyroid Disease
- Thyroid Neoplasms
- Neuroectodermal Tumors
ARROW Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
ARROW Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
ARROW Trial Design
Find a Location
Who is running the clinical trial?
- You have tumors in your brain or spinal cord that are causing worsening neurological symptoms.You have a lung disease that causes symptoms or inflammation, such as radiation-related lung problems.You have been diagnosed with another type of cancer and received treatment within the past year.Your disease cannot be surgically removed.
- Group 1: Phase 1 Dose Escalation
- Group 2: Phase 2 Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other experiments have been undertaken to explore the efficacy of pralsetinib (BLU-667)?
"Currently, a total of 7 studies for pralsetinib (BLU-667) are in progress, 3 of which have reached Phase 3. 677 medical facilities across Cordoba and Calabria are conducting trials to assess the efficacy of this intervention."
What is the estimated number of participants in this clinical trial?
"Unfortunately, this trial is not currently accepting new participants. Initially posted on March 17th 2017 and last updated November 10th 2022, it has since been concluded. However, there are 8906 medical studies actively recruiting patients with neoplasms by site as well as 7 trials searching for volunteers to test pralsetinib (BLU-667)."
Has this investigation been conducted before?
"Pralsetinib (BLU-667) is currently in the midst of 7 clinical trials conducted across 175 cities and 45 countries. The drug was initially tested by Hoffmann-La Roche back in 2017, with 589 patients enrolled for their Phase 1 & 2 study. Since then, no further studies have been completed."
How many healthcare facilities have implemented this research project?
"The current trial is being conducted in 35 medical facilities, including those found in Albany, Jacksonville and Phoenix. To reduce travel-related stressors, participants are urged to select a location nearest them."
Is the research team at this moment seeking participants for the trial?
"This clinical trial is no longer taking on new participants. It was initially posted in March of 2017 and last updated in November of 2022. If you are still searching for medical studies, there are currently 8906 trials recruiting patients with neoplasms by site and 7 specifically related to pralsetinib (BLU-667)."
What conditions has pralsetinib (BLU-667) been found to be efficacious for?
"Pralsetinib (BLU-667) is typically prescribed for medullary carcinoma of the thyroid, though it may have some efficacy in treating radioiodine refractory conditions of the adrenal medulla that necessitate systemic treatment."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends